Peptides DB
Research-centric peptide and protocol reference hub

FOXO4-DRI (FOXO4-D-Retro-Inverso) record · updated 7h ago

Healing & recoveryInflammation & immuneGrade C · preclinicalResearch use only
All 1 studiesJump to the evidenceCompare
What is FOXO4-DRI (FOXO4-D-Retro-Inverso) used for?

FOXO4-DRI is a synthetic D-retro-inverso senolytic peptide designed to disrupt the FOXO4-p53 interaction and trigger selective apoptosis in senescent cells in preclinical longevity research.

Primarily researched for · Healing & recovery

Development stage

where FOXO4-DRI (FOXO4-D-Retro-Inverso) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.

Identity
NameFOXO4-DRI (FOXO4-D-Retro-Inverso)
Full name—
Sequence—
ClassLongevity
Research levelEmerging
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
Healing & recovery: Healing 3.0, Muscle 0.0, Metabolic 2.0, Neuro 1.0, Sleep 0.0, Immune 3.0, Skin 0.0Healing & recovery — 3.0 / 5Metabolic & appetite — 2.0 / 5Neuro & mood — 1.0 / 5Inflammation & immune — 3.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin3.00.02.01.00.03.00.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies1
Human / animal / cellular0 / 0 / 0
Highest trial phasePreclinical
Years covered2026
Latest study14d ago
Publication history
20262026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

1 rowOpen in the library →
StudyTypeYearSummary depth
FOXO family and neurodegenerative diseases: Mechanisms of action and therapeutic potential.
TakeawayFOXO transcription factors play diverse roles in neurodegenerative diseases, but effective therapies targeting these pathways are still in early development stages.
review2026Full text read0.70

Articles mentioning FOXO4-DRI (FOXO4-D-Retro-Inverso)